GlassScriptPhysician profile
James M Arons
NPI 1558351643
$2,343.97
in general payments reported to CMS, 2019-2025
29 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $145 · 2022: $78.99 · 2023: $75.83 · 2024: $94.71 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $306.08 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $256.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.26 | 2019-2020 | |
| Viiv Healthcare Company | $207.80 | 2022-2025 | Apretude |
| Janssen Pharmaceuticals, INC | $197.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $156.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $95.73 | 2019 | |
| Gilead Sciences, INC. | $93.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.38 | 2019-2020 | |
| Lilly USA, LLC | $80.66 | 2019-2025 | Zepbound |
| Amgen INC. | $74.29 | 2019-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $48.42 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $46.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.13 | 2019-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $43.69 | 2019 | |
| Dexcom, INC. | $26.78 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $26.78 | 2025 | Neffy |
| Biotronik Nro, INC. | $25.24 | 2025 | Prospera |
| Astellas Pharma US INC | $23.80 | 2019 | |
| Adlon Therapeutics L.P. | $19.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.05 | 2019 | |
| Abbvie INC. | $17.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.52 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.15 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2019 | |
| Allergan, INC. | $14.31 | 2019 | |
| Phadia US INC. | $12.33 | 2019 | |
| Cranial Technologies, INC | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Arons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.